Table 3A.
The outcomes in lung cancer patients among the included studies.
| Study | Median OS times | p-value | Survival rates, mortality | p-value | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| NN patients | HN patients | NN patients | HN patients | HR | 95% CI | p-value | ||||
| Yang et al. (27) | 1.1 ± 0.42 year | 0.83 ± 0.35 year | <0.05 | 62.26% 1-year SR 1.89% 5-year SR |
30.36% 1-year SR 0% 5-year SR |
0.045 0.15 |
NR | - | - | - |
| Osterlind et al. (28) | NR | NR | - | NR | NR | - | NR | - | - | - |
| Zarzecka et al. (29) | NR | NR | - | 7.8% mortality | 28.7% mortality | 0.0001 | NR | - | - | - |
| Hermes et al. (30) | 13 months | 9 months | <0.001 | NR | NR | - | I | - | - | 0.025 LD 0.038 ED |
| Wang et al. (31) | 14.5 months | 11.4 months | <0.001 | NR | NR | - | I | 1.82 | 1.34–2.47 | 0.007 |
| Berardi et al. (32) | 15.5 months | 8.78 months | <0.001 | 57.06% SR | 33.33% SR | 0.19 | I | 1.59 | 1.14–2.21 | 0.006 |
| Sengupta et al. (33) | NR | NR | - | NR | NR | - | NI | - | - | NS |
| Kobayashi et al. (34) | NR | NR | - | 74.8% 5-year SR | 59.7% 5-year SR | 0.002 | I | 1.53 | 1.01–2.32 | 0.047 |
| Fucá et al. (35) | 11.6 months | 2.8 months | <0.001 | 39.76% SR at 10 months | 15.38% SR at 10 months | - | I | 3.11 | 1.91–5.05 | <0.001 |
| Alamoudi (36) | NR | NR | - | NR | NR | - | NR | - | - | - |
| Hansen et al. (37) | 11.2 months | 7.1 months | 0.0001 | 57.25% SR at 10 months | 27.27% SR at 10 months | - | I | 1.6 | 1.27–2.01 | <0.001 |
| Svaton et al. (38) | 10.9 months | 4.6 months | <0.001 | 54.33% SR at 10 months | 21.36% SR at 10 months | <0.001 | I | 1.87 | 1.47–2.39 | <0.001 |
OS, overall survival; NN, normonatremic; HN, hyponatremic; NR, Not reported; S-significant; NS, not significant; I, Independent factor; N.I., Not independent factor; HR, hazard ratio; RR, risk ratio; SR, Survival rate; CI, confidence interval; LD, Limited Disease; ED, Extensive Disease.